Eupraxia Pharmaceuticals (EPRX) Interest & Investment Income (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Interest & Investment Income of $1.1 million for Q1 2026, up 247.09% year-over-year from $309452.0 in Q1 2025, and up 61.05% quarter-over-quarter from $666921.0 in Q4 2025.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Interest & Investment Income (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Interest & Investment Income for 4 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 247.09% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $2.2 million (up 76.57% YoY), while the FY2025 annual figure was $1.4 million, up 21.77% from the prior year.
- Interest & Investment Income advanced to $1.1 million in Q1 2026 per EPRX's latest filing, from $666921.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.1 million in Q1 2026 and bottomed at $152271.0 in Q2 2023.
- Historically, Interest & Investment Income has averaged $346884.6 across 4 years, with a median of $255958.0 in 2025.
- Annual changes were most pronounced in 2025 — Interest & Investment Income tumbled 40.8% — and 2026, when it soared 247.09%.
- Eupraxia Pharmaceuticals' Interest & Investment Income stood at $353790.0 in 2023, then tumbled by 38.38% to $218006.0 in 2024, then surged by 205.92% to $666921.0 in 2025, then surged by 61.05% to $1.1 million in 2026.
- Business Quant data shows EPRX's Interest & Investment Income at $1.1 million in Q1 2026, $666921.0 in Q4 2025, and $180185.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Eupraxia Pharmaceuticals | 304.67 Mn | 304.67 Mn | - | 1.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 666,921.00 |
| Sep 30, 2025 | 180,185.00 |
| Jun 30, 2025 | 255,958.00 |
| Mar 31, 2025 | 309,452.00 |
| Dec 31, 2024 | 218,006.00 |
| Sep 30, 2024 | 304,342.00 |
| Jun 30, 2024 | 401,226.00 |
| Mar 31, 2024 | 236,369.00 |
| Dec 31, 2023 | 353,790.00 |
| Sep 30, 2023 | 193,875.00 |
| Jun 30, 2023 | 152,271.00 |
| Mar 31, 2023 | 163,033.00 |